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Abstract
Background: Monoamine oxidase (MAO) enzymes play a critical role in controlling the catabolism of monoamine
neurotransmitters and biogenic trace amines and behavior in humans. However, the mechanisms that regulate
MAO are unclear. Several transcription factor proteins are proposed to modulate the transcription of MAO
gene, but evidence supporting these hypotheses is controversial. We aimed to investigate the mechanism of
gene transcription regulator proteins on amphetamine-induced behavior. We applied aptamers containing a DNA
binding sequence, as well as a random sequence (without target) to study the modulation of amphetamine-induced
MAO levels and hyperactivity in living mice.
Methods: We pretreated in adult male C57black6 mice (Taconic Farm, Germantown, NY) (n ≥ 3 litters at a time), 2 to
3 months of age (23 ± 2 gm body weight) with double-stranded (ds) DNA aptamers with sequence specific
to activator protein-1 (5ECdsAP1), nuclear factor-kappa beta (5ECdsNF-kB), special protein-1 (5ECdsSP-1) or
cyclicAMP responsive element binding (5ECdsCreB) protein binding regions, 5ECdsRan [a random sequence
without target], single-stranded AP-1 (5ECssAP-1) (8 nmol DNA per kg) or saline (5 μl, intracerebroventricular
[icv] injection) control before amphetamine administration (4 mg/kg, i.p.). We then measured and analyzed
locomotor activities and the level of MAO-A and MAO-B activity.
Results: In the pathological condition of amphetamine exposure, we showed here that pretreatment with
5ECdsAP1 and 5ECdsNF-kB reversed the decrease of MAO-A activity (p < 0.05, t test), but not activity of the
B isomer (MAO-B), in the ventral tegmental area (VTA) and substantia nigra (SN) of C57black6 mice. The change in
MAO-A level coincided with a reversed amphetamine-induced restless behavior of mice. Pretreatments with saline,
5ECdsCreB, 5ECdsSP-1, 5ECdsRan or 5ECssAP-1 had no effect.
Conclusion: Our data lead us to conclude that elevation of AP-1 or NF-kB indirectly decreases MAO-A protein levels
which, in turn, diminishes MAO-A ability in the VTA of the mesolimbic dopaminergic pathway that has been implicated
in cells under stress especially in the SN and VTA. This study has implications for design for the treatment of drug
exposure and perhaps Parkinson’s dementia.
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Background
Amphetamine-type stimulants (Ecstasy, methampheta-
mine, 3-4-methylenedioxymethamphetamine (MDMA or
MOLLY]) are second only to marijuana as the top drugs
of abuse worldwide (2011 Global ATS assessment, a
United Nations report). According to the National Drug
Abuse Warning Network, the emergency room visits were
more than double from 2004 to 2009 due to taking
MDMA alone or in combination with pharmaceuticals,
alcohol or both. MDMA is a Schedule I drug and its use
has the potential for abuse and impairment in learning [1],
aggressive behavior as well as symptoms such as those
seen in schizophrenia and depression [2, 3]. The
mechanism of action is not totally understood, except
that amphetamine and its analogs induce elevation of
gene transcription regulator proteins AP-1 and NF-
kB. Both transcription factors are known to response
to oxidative stress, inflammatory and apoptotic signals
[4], but reduce striatal astrocyte population with a
concomitant elevation of astrocytes in the subventri-
cular zone, a clear indication of brain damage [5].
The relationship between elevations of oxidative bio-
markers and abnormal psycho-physiological behavior after
amphetamine is less clear. Recently, it was shown that
amphetamine could reduce MAO-A among others pro-
teins [6], and importantly this was found in HIV-1 trans-
genic rats which normal metabolism of the brain may
have been altered [7].
MAO catalyzes the oxidative deamination of en-
dogenous monoamines in the human body [8]. There
are two isoforms of MAO (MAO-A and MAO-B), lo-
calized in outer mitochondrial membrane; they are
distributed throughout the nervous system as well as
other regions of the body including the digestive and
circulatory systems. MAO-A deficiency resulting from
mutation in the MAO-A gene can cause a characteris-
tic set of symptoms (i.e., mild mental retardation, im-
pulsive antisocial behavior, and mood and panic
disorders) collectively referred to as Brunner syn-
drome [9]. Mutations in the mouse MAO gene confer
the same phenotype [10]; therefore, the mouse is an
ideal animal model for preclinical experiments involv-
ing MAO-A manipulation.
Interestingly, elevated transcription factor proteins
AP-1 and NF-kB and microglial activation are also
known associations in ischemia-reperfusion injury, Par-
kinson disorder model, and human immunodeficiency
viral infection. Variation in MAO-A expression has been
associated with polymorphisms in the promoter region
[11, 12], which was also shown to contain at least one
consensus sequence for AP-1 and SP-1 binding [13–16].
To better understand how these two TF proteins may
influence MAO-A activity, we have taken an alternative
approach using a double-stranded (ds) DNA aptamer
with consensus sequences for these TF proteins. We
have demonstrated the specific and sensitive binding
of the dsAP1 and dsNF-kB aptamers to AP-1 and
NF-kB proteins, respectively [5], including a null
binding to the AP-1 aptamer in mice with mutant
AP-1 proteins [17]. MAO-A is found in the cyto-
plasm of dopaminergic neurons in the SN, pars com-
pacta, hypothalamus and VTA of the midbrain.
Because the mesolimbic neurons of the reward path-
way have axonal projections originating from the
VTA, we examined MAO-A antigen in the VTA re-
gion. Here, we correlate the effect of dsAP-1/NF-kB
aptamers on motor activities with MAO-A expression
in the VTA of live mice exposed to amphetamine.
Methods
Animals and housing
All of the procedures used in this study were approved by
the Massachusetts General Hospital Subcommittee on
Research Animal Care, the institutional animal welfare
committee, in accordance with the Public Health Service
Guide for the Care and Use of Laboratory Animals. Adult
male C57black6 mice (Taconic Farm, Germantown, NY)
(n ≥ 3 litters at a time), 2 to 3 months of age (23 ± 2 gm
BW), were kept in cages on sawdust bedding, in a room
with controlled light cycles (12 h light/12 h dark), where
they had free access to water and were fed standard lab
chow. Mice were trained, operated on, and tested in a ran-
domized manner, with a blinded observer performing the
behavioral testing.
Short dsDNA for AP1 binding protein
Double-stranded DNA containing the consensus sequence
(denoted by uppercase letters) for AP1 protein (5’-fluore-
cein isothiocyanate [FITC]-tccggcTGACTCAtcaagcg-3’
and 3’-aggccgACTGAGTagttcgc-biotin-5’) were modified
by phosphorothioation, a process by which sulfur replaces
non-bridging oxygen on the phosphate linkages of three,
four, or five nucleotides (lowercase letters) from both ends
(end caps, EC). Additional 5ECdsDNAs for transcription
factors include SP1 (5ECdsSP-1, 5’-ctcgcCCCGCCccgatc-
gaa-biotin and 3’-gagcgGGGCGGggctagctt); nuclear fac-
tor kappa beta (5ECdsNF-κβ, 5’-agttgaGGGGACTTTCC
caggc-biotin and 3’ tcaactCCCCTGAAAGGgtccg) and
cyclic AMP response element binding protein (5ECd
sCREB, 5’-ctctcTGACGTCAggcaat-biotin and 3’-gagag
ACTGCTGTccgtta). When single-stranded DNA was
used as a control, the oligoDNA was fully modified by
phosphorothioation.
Both strands of the transcription factor binding se-
quences were mixed at room temperature, heated at 65 °C
for five minutes, and slowly cooled on a thermocycler
(1 degree drop per minute) to 20 °C, at which
temperature they were maintained for 30 min. Short
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dsDNAs were stored in aliquots of 0.05 ml (100 μM)
at −20 °C. One hour before use, one aliquot was
thawed to room temperature.
Delivery of 5ECdsDNA aptamers
For uptake studies we anesthetized the mice with pure O2
plus 2 % halothane at a flow rate of 800 ml/min, and deliv-
ered the dsDNA aptamers (8 nmol DNA per kg, n = 4
each) by icv injection [18, 19], an accepted route of deliv-
ery for administering contrast agents to rodents and non-
human primates [20–22]. We delivered 8 nmol DNA per
kg (icv) for TF protein knockdown studies [23]. Three
hours after DNA delivery we administered either saline
(0.1 ml, i.p.) or amphetamine (4 mg per kg, i.p.). The up-
take of various 5EDdsDNA aptamer was performed and
validated as described previously; all photographs were
obtained with the same exposure time, using a Himatsu
CCD camera on an Olympus microscope (Optical Ana-
lysis Corp, NH) [5].
Behavioral testing after amphetamine
All mice were preconditioned for at least 48 h in the
testing cage, which was equipped with a locomotion de-
tector [21]. We delivered dsDNA or a control (icv) three
hours before we administered amphetamine [23]. After
amphetamine delivery the mice were immediately placed
in their home cages, where we measured their locomo-
tion for 60 min.
Animal handling
In order to minimize the effect of stress animals may ex-
perience by being in different environments before and
during amphetamine stimulation, each mouse was housed
in the same cage throughout the experiments, which in-
cluded one week of habituation to a new environment.
Three days before amphetamine pre-treatment, we habitu-
ated all animals by administering a daily injection of saline
solution (0.25 ml) and assessing behavior as baseline on
each day. Each home cage was placed directly in the auto-
matic recording system before animals received their am-
phetamine injection. We divided animals into two groups
to receive either amphetamine or saline (vehicle) pretreat-
ment for the subsequent days. The mice were never placed
in a new cage for behavioral assessment as described [21].
MAO protein expression
Immunohistochemistry
We delivered saline, dsAP1, or dsRan to mice by icv in-
jection (2 μl), and amphetamine described above; tissue
samples were obtained from mice 90 min after amphet-
amine. We measured MAO-A expression using rabbit
polyclonal antibodies against MAO-A(1:500, Novus Bio-
logicals, Littleton, CO, NBP1-19796) using a procedure
previously published [19].
Western blot of MAO protein expression
Tissue samples (5 mg) of mouse VTA were removed
after 90 or 180 min using a biopsy punch (Miltex Inc
York, PA); the samples were then snap frozen in liquid
nitrogen and homogenized using an ultrasonicator (Sonic
Dismenbrator Model 100, Fisher Scientific, Pittsburgh,
PA) in 100 μl of cold radioimmunoprecipitation assay lysis
buffer with a protease inhibitor cocktail (Sigma-Aldrich,
St. Louis, MO). The homogenate was then centrifuged for
10 min at 12,000 g at 4 °C. The protein concentration was
determined by the Bradford method (BioRad Protein
Assay, Hercules, CA), using a reference curve from bovine
serum albumin. Protein samples (10 μg each group) mixed
from four mice in each group, along with a molecular
weight marker ladder (10 KD ladder, Thermo Scientific,
Rockford, IL) were separated on a 20 % tris-glycine PAGE
(Invitrogen) and transferred to a PVDF membrane using a
semidry electrophoretic blotter (BioRad). The primary
rabbit polyclonal antibodies against MAO-A or MAO-B
were diluted at 1:1000 (Novus NBP-59569 for MAO-B).
Anti-actin rabbit polyclonal antibodies (1:1000 dilutions,
Abcam, ab1801, Cambridge, MA) were added with IgG
against MAO for control detection. Chemiluminescent
detection was performed with a Western Breeze chemilu-
minescent kit (Invitrogen, Grand Island, NY) that includes
anti-rabbit secondary antibodies, and the signal was
captured on an X-ray film (Kodak BioMax XAR film, St.
Louis MO). Quantitative densitometry of protein bands
was performed using an image-processing program
(FluorChem Q, Alpha Innotech, San Jose, CA). In addition
to the VTA proteins, housekeeping β-actin proteins were
used as normalizing factors, and as an indicator of the
quality of antibody binding. All assays were repeated at
least twice to ensure reproducibility.
Statistical analysis
Once we had obtained the first data set, we calculated
the number of animals needed in each group to achieve
95 % power for a p value of 0.01 [21, 24]. We computed
the mean and standard error of the mean (SEM) from
the average values in each group of animals, and
compared the statistical significance of these values
using a t test (one tail, type II or equal variant,
GraphPad Prism IV, GraphPad Software, Inc., San
Diego, CA). A p value of less than 0.05 was statisti-
cally significant.
Results
Amphetamine reduces MAO-A antigen level
We found the presence of MAO-A in the cytoplasm of
dopaminergic neurons, which in naïve mice are present
chiefly in the SN, pars compacta, hypothalamus and
VTA of the midbrain (circles, Fig. 1a). In normal mouse
brains without amphetamine MAO-A is distributed
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within the soma and axons of the neurons in the VTA
(boxes, Fig. 1b). Amphetamine treatment reduced MAO-
A antigen in the mesolimbic neurons of the SN, ventral
striatum and VTA (boxes, Fig. 1c).
To investigate the mechanism by which amphetamine
reduces MAO-A, we applied aptamers with consensus
sequences for TF proteins as well as one aptamer with
random (Ran) sequence, which has no intracellular tar-
get. We applied 5ECdsAP1 or 5ECdsNF-kB (n ≥ 2 each
group) to mice according to the protocol outlined in
Fig. 1d. Mice with 5ECdsAP1 or 5ECdsNF-kB aptamer
pretreatment showed a reversal of amphetamine-induced
MAO-A reduction in the soma of the VTA neurons as
well as in the axons of neurons in the SN (Fig. 1e).
Modulation of transcription factor AP-1 protein on
MAO-A activity
We quantitatively measured MAO-A level by Western
blot, using Actin as a control. MAO-A antigen levels, as
measured in VTA samples (n ≥ 3 each lane, three
Fig. 1 The expression of MAO-A antigen in the CNS (no injection, panel a) in mice after saline (100 μl, i.p., panel b) or amphetamine (4 mg/kg, s.c., panel c) as
shown in the protocol (panel d). Pretreatment of AP-1 or NF-kB Aptamer reverses AMPH-induced MAO-A deficiency (panel e). Mice pretreated with 5ECdsAP-1
or 5ECdsNF-kB aptamer before amphetamine (AMPH) show a reversal of MAO-A protein expression. MAO-A protein is present in the cytoplasm of the soma in
the VTA (ventral tegmental area and axons in the SN (substantia nigra) and VS (ventral striatum) of the mesolimbic pathway. Immunohistochemistry results
suggested that 5ECdsAP-1 might have a different temporal effect from 5ECdsNF-kB did on the reversal of MAO-A antigen level
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measurements or 12 – 15 mice) collected 90 min after am-
phetamine (Fig. 2a), were elevated with 5ECdsAP1 pretreat-
ment (lane 4, Fig. 2a). A half dose of 5ECdsAP1 (4 nmol/
kg) did not reverse amphetamine’s effect on MAO-A (lane
2). The results that we acquired 180 min after amphet-
amine exposure showed only slight elevation, with no sig-
nificant difference in MAO-A levels associated with either
5ECdsAP1 treatment (lane 6) or naïve mice (lane 8, Fig. 2a).
MAO-B expression was unchanged in the same sets of
samples (Fig. 2b). Pretreatment with 5ECdsNF-kB reversed
MAO-A activity (Fig. 2c). Moreover, we observed no sig-
nificant change in MAO-A level following pretreatment
with either control (5ECdsRan or saline), single-stranded
aptamer (ssAP1) 5ECdsSP1 or 5ECdsCREB aptamers
(Fig. 2c); these results thus establish that the reversal of
MAO-A reduction is significant and specific to 5ECdsAP1.
Furthermore, RT-PCR and TaqMan analysis showed no
significant change in MAO-A mRNA before and after
5ECdsAP1 and amphetamine administration (p = 0.05, t
test, two n = 4 samples from each group). Together these
data reveal that amphetamine exposure reduces MAO-A
protein, which in turn produces an antagonist effect on
amphetamine-induced acute stress behaviors. We conclude
that the modulation of MAO-A level in the VTA is in-
versely related to AP-1 transcription factor expression.
5ECdsAP1 ameliorates amphetamine-induced motor
activity
We recorded and measured locomotor activities using an
automatic recording system in a controlled environment
[21]. We then compared the effect on motor activity by
measuring the distance the mice traveled when given a
minimum dose of 8 nmol/kg of 5ECdsAP1, 5ECdsNF-kB,
5ECdsRan or saline. We observed that pretreatment with
5ECdsAP1 or 5ECdsNF-kB aptamer significantly sup-
pressed an amphetamine-induced increase in locomotor
activity (p < 0.05). We did not observe in this suppression
of amphetamine-induced hyperactivity in control mice
that received saline or 5ECdsRan (not shown) before am-
phetamine (Fig. 3). Moreover, 5ECdsAP1 with complete
phosphorothioate linkage (dsAP1, All EC), which is
known to have sticky properties for all proteins, partially
attenuated the hyperactivity suppression effect. A half
dose of 5ECdsAP1 (i.e., 4 nmol/kg, icv) had no significant
effect on hyperactivity suppression, nor did single-
stranded sODN-AP1 (ssAP-1) at full dose (not shown).
Discussion
Amphetamine exposure induces elevations in immediate
early genes and their products; however, the relationship
of such changes in gene expression to amphetamine in-
duced restless activity is not clear. Here, we have applied
nucleic acid aptamers to to AP-1 and NF-kB and exam-
ined how MAO-A and MAO-B proteins modulate
amphetamine-induced hyperactivity. Our results show
that AP-1 and NF-kB activities are responsible for the
reduction in the level of MAO-A, but not MAO-B, by a
post transcription pathway; the effect of MAO-A change
is inversely related to hyperactivity after amphetamine.
A reduced level of MAO-A correlates with hyperactive
Fig. 2 MAO-A and MAO-B levels after amphetamine. We pretreated mice with 5ECdsAP1 aptamer before amphetamine application according
to Fig. 1d; we collected tissue samples (n = 4 per group) from the VTA at 90 (60 + 30 min Fig. 1d) and 180 (60 + 30 + 90 Fig. 1d) minutes after
amphetamine. We obtained protein for Western blot quantitation of MAO-A (panel a) or MAO-B (panel b) level (upper molecular fragments) using
Actin (lower molecular fragments) as a reference shown in lanes 2–4 (90 min samples) or lane 5–6 (180 min). Total protein (10 μg) was used for
all lanes except lanes 7 & 9. The blot was stripped and used for MAO-B after MOA-A. Lane 1: molecular size marker of 10 KD ladder; lane 2: 5ECd-
sAP1 (4 nmol/kg, icv, half dose); lanes 3 & 5: saline (2 μl, icv); lanes 4 & 6: 5ECdsAP1 (8 nmol/kg, icv, full dose); lanes 7, 8, 9 are controls of naive
mice (no aptamer or amphetamine (with increasing amount of protein: 5, 10 and 20 μg, respectively. Because we observed no change in MAO-B
level (Panel b), we determined 90 min post amphetamine is the optimal time to collect VTA samples (panel a, lane 4) for quantitative comparison
of the reversal of MAO-A level in the VTA tissue from mice treated with 5EC aptamers of dsAP1, ssAP1, dsNF-kB, saline (Sal), nothing (naïve), dsSP1,
dsCREB, and dsRan (panel c). Aptamer 5ECdsAP1 elevated the MAO-A by 60–100 % (t test, shown as bar graphs in panel c). N = number of mice
used in the test
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behavior; our study suggests that MAO-A induced ag-
gressive behavior can be modulated via epigenetic
means. We show that a reduced MAO-A level (Fig. 1)
without changing MAO-B level (Fig. 2) caused abnormal
behavior (Fig. 3); phenomenon observed also in humans
and in rats [7]. Although this observation is different
from consensus understanding that MAO-B activities
metabolize dopamine in normal condition of human
brains [25], we believe there was no conflicts because
the modulation of MAO-A we studied is pathological
condition during amphetamine exposure where we ob-
served a resistance of MAO-B to amphetamine. Our
study also supports results from a study showed that
NF-kB protein knockdown using antisense strategy re-
duced amphetamine-mediate feeding suppression [26].
Indeed, hyperthermia, oxidative stress, neuro-toxicity and
striatal neuroglia loss are severe complications associate
with amphetamine exposure [27]; AP-1 and/or NF-kB TF
proteins can initiate these biological processes. However,
most studies have suggested that the hyperactivity ob-
served in association with amphetamine results from
altered neurotransmitter activities in dopaminergic
neurons of the mesolimbic pathway, which to date has
been regarded as resulting from a dopamine transporter-
mediated elevation in extracellular monoamine [28]. Here,
we show using aptamer competing with AP-1/NF-kB TF
protein binding that MAO-A level is reversed in the VTA
leading to suppression of amphetamine-induced behav-
ioral abnormality in the animal.
Our study demonstrates the specificity of the aptamer
for MAO-A, as 5ECdsAP1 had no effect on MAO-B.
This specificity supports regulation of different pathways
by these two isomers [29, 30]. Because our aptamer ef-
fectively competes with in vivo TF proteins, which are
hetero- and/or homo-dimeric forms of at least two gene
families, our aptamer provides a direct approach to gene
knockdown of proteins and acts as an antagonist indir-
ectly modulating the level of MAO-A protein.
Our observation that specific reduction of MAO-A pro-
tein happened without significant change in MAO-A
mRNA in the VTA after amphetamine exposure, suggests
that MAO transcription activity is not affected directly by
TF-mediated regulation on MAO genes, especially involv-
ing the SP-1 transcription factor [31]. We propose that
Fig. 3 Amphetamine-induced hyperlocomotor activity in the control group [pretreatment with 5ECdsRan (panels a & b) or saline (panels c & d)
before amphetamine] is reversed to near normal levels when mice were pretreated with 5ECdsAP1 (panels a – d) or 5ECdsNF-kB (panels c & d).
Other control group not shown in this graph is pretreatment with ssAP-1 (fully phosphorothioate-modified). Fine motor movement (front paw
movement without changing body position) is shows as frequency per minute (panel b). Distance traveled is given at speed (m per hr (panel a)
or in centimeters at each interval of 5 min (panels c & d, which was calculated by the frequency of ambulation (locomotion between adjacent
beams of light of 5 cm in one minute) x 5 cm per minute x 5 min per recoding interval. Typically, normal mice without treatment exhibited no
more than 30 ambulation frequency per min within 15 min after handling (baseline). No significance was found between the control (saline) and
dsAP-1 of Full EC (panel c)
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the reduction in MAO-A protein may be a result of cata-
bolic action to exogenous amphetamine detoxification,
most likely as an inflammatory reaction related to AP-1/
NF-kB TF proteins. Moreover, the absence of significant
MAO-A mRNA elevation after amphetamine suggest that
the reduction in MAO-A does not produce a feedback sig-
nal fast enough to increase MAO-A transcription, or the
signal is blocked by a suppressor. The suppressor hy-
pothesis supports the result of histone deacetylation
on the promoter of c-fos gene [32]. The mechanism
proposed here may also explain the null effect that
cocaine elicits on hyperactivity observed in other
studies in a double-transgenic mouse strain that pro-
duces no active AP-1 TF protein [17].
Both AP-1 and NF-kB TF proteins are known to increase
after amphetamine exposure. Similar phenomenon has
been described in animal models of ischemia reperfusion
brain injury, major mood disorder and/or bipolar disorder,
Parkinson disease [33, 34] and in human populations in-
fected with sexually transmitted infections [4, 35, 36].
Acute stress, characterized by anxiety (insomnia, irritabil-
ity, poor concentration, motor restlessness), among other
human conditions, can be experimentally induced in ani-
mals [37, 38]. Given that reduced MAO-A protein levels
are associated with acute stress in humans [39], we envi-
sion that our 5ECdsAP1/5ECdsNF-kB aptamer may be
applied, in theory, to correct abnormal MAO-A expression
observed during acute stress.
OligoDNA antisense to Fos gene families reduced TF
protein by knockdown of respective mRNA [40, 41]. We
have shown that aptamer 5ECdsAP-1 or 5ECdsNF-kB
targets AP-1 or NF-kB TF protein on a gel shift assay,
respectively [5]. Specific targeting in living brains mediate
MRI of intracellular TF protein at low dose and reduce
amphetamine-mediated MAO-A enzyme degradation and
stress activities at high dose. The latter event keeps a nor-
mal level of MAO-A in the mesolimbic dopaminergic
neurons supports that MAO-A level is inversely pro-
portional to hyperactivity. The data supports the asso-
ciation of MAO-A activity and normal behavior [10].
Therefore, our study confirms that targeting MR-CA
using aptamers can have a potential for theranostic
application [21].
We did not observe a complete reversal of amphetamine-
induced hyperactivity in response to dsAP1 with total
phosphorothioation (Fig. 2). We attribute this effect
to nonspecific binding of the aptamer to other pro-
teins, which hence dilutes the effective binding on the
target AP-1 protein. A number of studies by other in-
vestigators have used aptamers to target different TF
proteins [42–45]. In addition to 5ECdsCreb aptamer,
5ECdsSP-1 failed to modulate MAO-A level because
SP-1 binding site is absent from the human promoter of
the MAO-A gene but can be found at the promoter of the
human MAO-B gene [31]. We have clarified the mechan-
ism by which the aptamer mitigates amphetamine-related
hyperactivity via MAO-A attenuation; our method,
therefore, provides an additional means to evaluate
the mechanism and the internal trafficking of these
TF proteins in vivo.
Conclusion
Because aptamer can be labeled with iron oxide nano-
particles, gold, or fluorescent dyes our approach may be
applied for multimodal imaging using MRI (in vivo) and
microscopy (ex vivo). The results are consistent with the
report that 5ECdsAP1 or 5ECdsNF-kB can specifically
guide the delivery of DNA or contrast agents to the cells
that contain the target of unique intracellular TF pro-
teins. Furthermore, an intracerebroventricular injection,
which directly bypasses the blood–brain barrier, is clinic-
ally accepted for delivery of therapeutic agents, validat-
ing the translational potential of our approach. We
anticipate that this technique will have potential for real-
time and longitudinal research, in preclinical as well as
for clinical applications.
Abbreviations
FITC: fluorescein isothiocyanate; Icv: intracerebroventricular; MAO-
A: monoamine oxidase-A; NAc: nucleus accumbens; SN: substantia nigra;
TF: transcription factor; VTA: ventral tegmental area.
Competing interests
The authors declare no competing financial interests.
Authors’ contributions
JR carried out delivery, histology and western blot, both CHL and JR carried out
behavior and data analysis, and PKL designed apdamer and experiment and
wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Drs. M. Schwartzchild for allowing us to use the locomotion
detection device and Charng-Ming Liu for modified aptamer ds-sODN. We
also thank Ms. N. Eusemann for assistance with editing the manuscript. This
project was supported by research grants R01DA029889 and R01EB013768 to
PKL, NS045776 to the MGH Neuroscience Center.
Author details
1Athinoula A. Martinos Center for Biomedical Imaging, Department of
Radiology, Massachusetts General Hospital, Charlestown, MA 02129, USA.
2Present address: NIH, 6707 Democracy Blvd, Suite 200, Bethesda, MD 20892,
USA.
Received: 24 August 2015 Accepted: 20 January 2016
References
1. Wagner D, Becker B, Koester P, Gouzoulis-Mayfrank E, Daumann J. A
prospective study of learning, memory, and executive function in new
MDMA users. Addiction. 2013;108(1):136–45.
2. Du L, Bakish D, Ravindran A, Hrdina PD. MAO-A gene polymorphisms are
associated with major depression and sleep disturbance in males.
Neuroreport. 2004;15(13):2097–101.
3. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al.
Elevated monoamine oxidase a levels in the brain: an explanation for the
monoamine imbalance of major depression. Arch Gen Psychiatry.
2006;63(11):1209–16.
Liu et al. Journal of Biomedical Science  (2016) 23:21 Page 7 of 8
4. Lee YW, Hennig B, Yao J, Toborek M. Methamphetamine induces AP-1 and
NF-kappaB binding and transactivation in human brain endothelial cells. J
Neurosci Res. 2001;66(4):583–91.
5. Liu CH, Ren J, Liu CM, Liu PK. Intracellular gene transcription factor protein-
guided MRI by DNA aptamers in vivo. FASEB J. 2014;28(1):464–73.
6. Moran LM, Booze RM, Webb KM, Mactutus CF. Neurobehavioral alterations
in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. Exp Neurol.
2013;239:139–47.
7. Moran LM, Aksenov MY, Booze RM, Webb KM, Mactutus CF. Adolescent HIV-
1 transgenic rats: evidence for dopaminergic alterations in behavior and
neurochemistry revealed by methamphetamine challenge. Curr HIV Res.
2012;10(5):415–24.
8. Premont RT, Gainetdinov RR, Caron MG. Following the trace of elusive
amines. Proc Natl Acad Sci U S A. 2001;98(17):9474–5.
9. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal
behavior associated with a point mutation in the structural gene for
monoamine oxidase A. Science. 1993;262(5133):578–80.
10. Chen K, Holschneider DP, Wu W, Rebrin I, Shih JC. A spontaneous point mutation
produces monoamine oxidase A/B knock-out mice with greatly elevated
monoamines and anxiety-like behavior. J Biol Chem. 2004;279(38):39645–52.
11. Hamilton SP, Slager SL, Heiman GA, Haghighi F, Klein DF, Hodge SE, et al.
No genetic linkage or association between a functional promoter
polymorphism in the monoamine oxidase-A gene and panic disorder. Mol
Psychiatry. 2000;5(5):465–6.
12. Wu JB, Chen K, Li Y, Lau YF, Shih JC. Regulation of monoamine oxidase A
by the SRY gene on the Y chromosome. FASEB J. 2009;23(11):4029–38.
13. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, et al.
Excess of high activity monoamine oxidase A gene promoter alleles in
female patients with panic disorder. Hum Mol Genet. 1999;8(4):621–4.
14. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine
oxidase A gene promoter. Hum Genet. 1998;103(3):273–9.
15. Schulze TG, Muller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, et al.
Association between a functional polymorphism in the monoamine oxidase
A gene promoter and major depressive disorder. Am J Med Genet.
2000;96(6):801–3.
16. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of
a monoamine oxidase a gene promoter polymorphism with major
depressive disorder and antidepressant response.
Neuropsychopharmacology. 2005;30(9):1719–23.
17. Paletzki RF, Myakishev MV, Polesskaya O, Orosz A, Hyman SE, Vinson C.
Inhibiting activator protein-1 activity alters cocaine-induced gene
expression and potentiates sensitization. Neuroscience. 2008;152(4):1040–53.
18. Liu CH, You Z, Ren J, Kim YR, Eikermann-Haerter K, Liu PK. Noninvasive
delivery of gene targeting probes to live brains for transcription MRI. FASEB
J. 2008;22(4):1193–203.
19. Liu CH, Ren JQ, You Z, Yang J, Liu CM, Uppal R, et al. Noninvasive detection of
neural progenitor cells in living brains by MRI. FASEB J. 2012;26(4):1652–62.
20. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, et al.
Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect
cortical neurons from excitotoxicity and reduce focal ischaemic infarctions.
Nature. 1993;363(6426):260–3.
21. Liu CH, Ren JQ, Yang J, Liu CM, Mandeville JB, Rosen BR, et al. DNA-based
MRI probes for specific detection of chronic exposure to amphetamine in
living brains. J Neurosci. 2009;29(34):10663–70.
22. Strome EM, Wheler GH, Higley JD, Loriaux DL, Suomi SJ, Doudet DJ.
Intracerebroventricular corticotropin-releasing factor increases limbic
glucose metabolism and has social context-dependent behavioral effects in
nonhuman primates. Proc Natl Acad Sci U S A. 2002;99(24):15749–54.
23. Liu PK, Salminen A, He YY, Jiang MH, Xue JJ, Liu JS, et al. Suppression of
ischemia-induced fos expression and AP-1 activity by an antisense
oligodeoxynucleotide to c-fos mRNA. Ann Neurol. 1994;36(4):566–76.
24. Liu CH, D’Arceuil HE, de Crespigny AJ. Direct CSF injection of MnCl(2) for
dynamic manganese-enhanced MRI. Magn Reson Med. 2004;51(5):978–87.
25. Glover V, Sandler M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B
substrate in man. Nature. 1977;265(5589):80–1.
26. Kuo DY, Chen PN, Kuo MH, Chen CH, Hsieh YS, Chu SC. NF-kappaB
knockdown can modulate amphetamine-mediated feeding response.
Neuropharmacology. 2012;62(4):1684–94.
27. Carvalho F, Duarte JA, Neuparth MJ, Carmo H, Fernandes E, Remiao F, et al.
Hydrogen peroxide production in mouse tissues after acute d-
amphetamine administration. Influence of monoamine oxidase inhibition.
Arch Toxicol. 2001;75(8):465–9.
28. Thomas DM, Francescutti-Verbeem DM, Kuhn DM. The newly synthesized
pool of dopamine determines the severity of methamphetamine-induced
neurotoxicity. J Neurochem. 2008;105(3):605–16.
29. Gould TJ, Keith RA, Bhat RV. Differential sensitivity to lithium’s reversal of
amphetamine-induced open-field activity in two inbred strains of mice.
Behav Brain Res. 2001;118(1):95–105.
30. Benmansour S, Brunswick DJ. The MAO-B inhibitor deprenyl, but not the
MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-
chloroamphetamine. Brain Res. 1994;650(2):305–12.
31. Ou XM, Chen K, Shih JC. Dual functions of transcription factors,
transforming growth factor-beta-inducible early gene (TIEG)2 and Sp3, are
mediated by CACCC element and Sp1 sites of human monoamine oxidase
(MAO) B gene. J Biol Chem. 2004;279(20):21021–8.
32. Renthal W, Carle TL, Maze I, Covington 3rd HE, Truong HT, Alibhai I, et al.
Delta FosB mediates epigenetic desensitization of the c-fos gene after
chronic amphetamine exposure. J Neurosci. 2008;28(29):7344–9.
33. Brody SA, Geyer MA, Large CH. Lamotrigine prevents ketamine but not
amphetamine-induced deficits in prepulse inhibition in mice.
Psychopharmacology (Berl). 2003;169(3–4):240–6.
34. Zhang Z, Andersen A, Grondin R, Barber T, Avison R, Gerhardt G, et al.
Pharmacological MRI mapping of age-associated changes in basal ganglia
circuitry of awake rhesus monkeys. Neuroimage. 2001;14(5):1159–67.
35. Shah A, Silverstein PS, Kumar S, Singh DP, Kumar A, et al. Synergistic
cooperation between methamphetamine and HIV-1 gsp120 through the
P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytes. PLoS
One. 2012;7(12):e52060.
36. Liu X, Silverstein PS, Singh V, Shah A, Qureshi N, Kumar A.
Methamphetamine increases LPS-mediated expression of IL-8, TNF-alpha
and IL-1beta in human macrophages through common signaling pathways.
PLoS One. 2012;7(3):e33822.
37. Komatsu T, Trindade LS, Chiba T, Hayashi H, Henmi T, Ushiroda Y, et al.
Acute stress response modified by modest inhibition of growth hormone
axis: a potential machinery of the anti-aging effect of calorie restriction.
Mech Ageing Dev. 2011;132(3):103–9.
38. Sterrenburg L, Gaszner B, Boerrigter J, Santbergen L, Bramini M, Roubos EW,
et al. Sex-dependent and differential responses to acute restraint stress of
corticotropin-releasing factor-producing neurons in the rat paraventricular
nucleus, central amygdala, and bed nucleus of the stria terminalis. J
Neurosci Res. 2012;90(1):179–92.
39. Soliman A, Udemgba C, Fan I, Xu X, Miler L, Rusjan P, et al. Convergent
effects of acute stress and glucocorticoid exposure upon MAO-A in
humans. J Neurosci. 2012;32(48):17120–7.
40. Shyu KG, Wang BW, Yang YH, Tsai SC, Lin S, Lee CC. Amphetamine activates
connexin43 gene expression in cultured neonatal rat cardiomyocytes
through JNK and AP-1 pathway. Cardiovasc Res. 2004;63(1):98–108.
41. Chiasson BJ, Hong M, Hooper ML, Armstrong JN, Murphy PR, Robertson HA.
Antisense therapeutics in the central nervous system: the induction of c-fos.
Methods Mol Med. 1996;1:225–45.
42. Ahn JD, Morishita R, Kaneda Y, Lee SJ, Kwon KY, Choi SY, et al. Inhibitory
effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth
muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res.
2002;90(12):1325–32.
43. Fennewald SM, Scott EP, Zhang L, Yang X, Aronson JF, Gorenstein DG, et al.
Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression
and the outcome of arenavirus infections. J Gen Virol. 2007;88(Pt 3):981–90.
44. Kume M, Komori K, Matsumoto T, Onohara T, Takeuchi K, Yonemitsu Y, et al.
Administration of a decoy against the activator protein-1 binding site
suppresses neointimal thickening in rabbit balloon-injured arteries.
Circulation. 2002;105(10):1226–32.
45. Stadlbauer TH, Wagner AH, Holschermann H, Fiedel S, Fingerhuth H, Tillmanns
H, et al. AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant
vasculopathy in rat cardiac allografts. Cardiovasc Res. 2008;79(4):698–705.
Liu et al. Journal of Biomedical Science  (2016) 23:21 Page 8 of 8
